U.S regulatory advisors have backed Lucentis for approval in treatment of diabetic macular edema. The FDA panel recommended the agency to approve a 0.5mg and 0.3mg dose of Lucentis in the treatment of DME. The FDA should decide sometime in August on the approval of the drug for as a treatment option. If approved, Lucentis would be the first drug approved for the treatment of diabetic macular edema.
Share knowledge, Stay informed
A Positive Voice for Students
Our Mission: To improve the profession of optometry by better educating and preparing students to enhance the lives and vision of their patients.
You might be interested in...
August 13, 2019 What You Need to Know Before Going on an Optometry Mission Trip
June 4, 2019 Computer Vision Syndrome: An Overview
March 20, 2019 Pediatric Awareness: Understanding Amblyopia